Semler Scientific had its Relative Strength (RS) Rating upgraded from 77 to 82 Monday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an 80 or better RS Rating in the early stages of their moves.
Semler Scientific has risen more than 5% past a 29.93 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% earnings growth in its most recent report. Revenue gains came in at -44%.
Semler Scientific earns the No. 43 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
